Bio-Path(BPTH) - 2023 Q3 - Quarterly Report

Company History and Available Information For the transition period from __________ to __________ CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Research and development expenses consist of costs associated with our research activities, including the development of our drug candidates. Our research and development expenses consist of: Revenue. We had no revenue for each of the three months ended September 30, 2023 and 2022. Delaware 87-0652870 (State or other jurisdiction of (I.R.S. Employer incorpora ...